Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progress
Eikon disclosed a completed interim analysis of its Phase 2/3 melanoma trial and $531.2 million in cash as of June 30, 2026, expected to fund operations into the second half of 2027.
SEC filing